Trial reportClinical and experimental dental research2025
Effectiveness of Recombinant Human Bone Morphogenetic Protein-2 in Socket Preservation: A Randomized Controlled Clinical and Sequential Human Histological Trial (BMP-2 TRIAL).
Trial report in Clinical and experimental dental research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Efficacy and safety of recombinant human bone morphogenetic protein-2 biomaterials in promoting bone regeneration: A systematic review and meta-analysis.Joint diseases and related surgery · 2026Pooled it
- Optimizing rhBMP-2 Therapy for Bone Regeneration: From Safety Concerns to Biomaterial-Guided Delivery Systems.International journal of molecular sciences · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesThe aim of this study was to evaluate the effectiveness of recombinant human bone morphogenetic protein-2 (rhBMP-2) coated biphasic calcium phosphate (BCP) in socket preservation in comparison to BCP. MATERIAL AND
methodsPatients who underwent extraction of maxillary premolars were randomized to receive rhBMP-2/BCP (n = 15) and BCP alone (n = 15). All sites were primarily closed using a pedicled connective tissue flap. Biopsy was carried out in patients at 3 (n = 10), 6 (n = 10), and 9 (n = 10) months.
resultsAt 3 months, BMP and non-BMP groups had 3.17% and 3.12% new bone formation, respectively, and 3.8% and 37.85% of residual grafts, respectively, and 25.86% and 25.99% connective tissue component, respectively. At 6 months, both groups revealed 67.42% and 16.55% essential bone growth, 1.74% and 3.04% of residual graft, and 1.3% and 67% connective tissue component, respectively. At 9 months, the BMP group revealed 93.6% new bone formation, 0.68% residual graft, and 1.9% connective tissue component, while the non-BMP groups had 23.35% new bone formation, 4.45% residual graft, and 44.06% connective tissue component.
conclusionThis study demonstrated that rhBMP-2 coated BCP significantly enhanced early graft substitution in socket preservation sites compared to BCP alone. There was a significantly higher percentage of new bone formation in the rhBMP-2/BCP group both at 6 and 9 months. Additionally, the rhBMP-2/BCP group exhibited faster resorption of the graft material and earlier maturation of newly formed bone. These findings strongly suggest that rhBMP-2/BCP can be an effective treatment modality for socket preservation, promoting predictable and accelerated bone regeneration.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.